Tue, May 16, 2023 page10

• Italy’s exports to China triple, but unclear why

  MYSTERY: Pharmaceuticals appear to be the focus of the export wave, particularly a drug purported to prevent COVID-19, but it alone does not explain the puzzling rise

  • Bloomberg
  • • 
    • 
    • 

  Italy’s exports to China have tripled in little more than a year. The problem is, even the experts are struggling to explain why.

  Shipments abroad rose above 3 billion euros (US$3.3 billion) in February, up 131 percent from a year earlier. This follows another jump of 137 percent the month before.

  For comparison, Italy exported about 1 billion euros of goods and services in January last year to the world’s No. 2 economy.

  

  Workers pull carts loaded with boxes past an empty storefront at a shopping and office complex in Beijing on April 14.

  Photo: AP

  Such a boom would be hard to explain under normal circumstances. Now, as Russia’s war in Ukraine and supply-chain upheaval distorts traditional trade flows, it is downright mysterious.

  First, consider the politics. Italy might be the only G7 country that has signed up to China’s mammoth investment plan, the Belt and Road Initiative, but the economic benefits of such an alliance since 2019 have been limited.

  Moreover, relations had already cooled significantly under former Italian prime minister Mario Draghi. His successor, Giorgia Meloni, has signaled to US officials that she would pull out of the controversial China deal before the end of the year.

  What makes the data even more puzzling is that it is all down to a specific sector: pharmaceuticals. To be more precise, “medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses.”

  Exports of this group of products rose to 1.84 billion euros in February from 98.5 million euros a year earlier. They accounted for almost two-thirds of all Italian exports to China.

  Why the spike? Italian media have speculated that the driving force is runaway Chinese demand for ursodeoxycholic acid (UDCA), a chemical used mostly in liver drugs and that has been claimed — without reason — to help prevent COVID-19.

  So the sudden end of China’s “zero COVID” strategy and the subsequent wildfire spread of the virus across the country might be behind the export boom, although the vast majority of China’s population appears to have gotten COVID-19 in December last year and January, meaning they would have recovered before Italian exports started rising.

  However, UDCA demand alone does not explain the export peak.

  Industria Chimica Emiliana Srl, the Italian company that is the world’s largest integrated producer of UDCA and bile acid products, has yearly sales of about 300 million euros, just a fraction of the jump in Italian pharma exports to China.

  Adding to the uncertainty, the most recent Chinese data yields little evidence these products are arriving en masse. Considering shipping times, the drugs — whatever kind they are — should have made it to China to be counted in last month’s trade data, but there was no observable change.

  One explanation might be shifting regional trade.

  “It’s likely demand for medicines from China,” said Peter Ceretti, a director at Eurasia Group who investigated the matter. “Larger Italian pharma producers are shipping as much Italian-made product as they can, and perhaps some are moving German and other European Union-produced medicine into Italy for re-export to China, too.”
• Most Popular

  • 1

    Cabinet mulls chip aid after Trump threat

  • 2

    AI scare to boost Taipei-US ties: expert

  • 3

    First Replicator initiative on track: US

  • 4

    Coast guard identifies 52 ‘suspicious’ Chinese ships

  • 5

    Manila arrests Chinese spies posing as Taiwanese